Evidence map›Paper›PMID 38301311›Full record

ArticleGynecologic oncology2024

Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.

Brian Befano, Nicolas Wentzensen, Thomas Lorey, Nancy Poitras, Li C Cheung, Mark Schiffman, Megan A Clarke, Camryn Cohen, Walter Kinney, Alex Locke and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Brian BefanoInformation Management Services, Calverton, MD, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Rockville, MD, USA.
Thomas LoreyKaiser Permanante, The Permanante Medical Group Regional Laboratory, Berkeley, CA, USA.
Nancy PoitrasKaiser Permanante, The Permanante Medical Group Regional Laboratory, Berkeley, CA, USA.
Li C CheungDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Rockville, MD, USA.
Mark SchiffmanDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Rockville, MD, USA.
Megan A ClarkeDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Rockville, MD, USA.
Camryn CohenDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Rockville, MD, USA.
Walter KinneySacramento, CA, USA.
Alex LockeSacramento, CA, USA.
Philip E CastleDivision of Cancer Epidemiology and Genetics, U.S. National Cancer Institute, Rockville, MD, USA; Division of Cancer Prevention, U.S. National Cancer Institute, Rockville, MD, USA. Electronic address: philip.castle@nih.gov.
Division of Cancer Epidemiology and GeneticsCalifornia State University, Sacramento · USNational Cancer Institute · US

Funding

Human papillomavirus (HPV) infection and cervical and anal cancersZIACP010124 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI WENTZENSEN, NICOLAS · 2009 to 2025
$17.3M
Developing Data-Driven Cancer ResearchersT32CA009168 · NCI · UNIVERSITY OF WASHINGTON · PI STEPHEN M SCHWARTZ, MICHAEL Chiao-An WU · 1985 to 2026
$10.1M
Global Cancer HealthZIACP101237 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI CASTLE, PHILIP · 2022 to 2025
$6.6M
Intramural NIH HHS ZIA CP010124Intramural NIH HHS ZIA CP101237NCI NIH HHS T32 CA009168
6 · The paper itself

Abstract

objectivesThe longer-term impact of introducing human papillomavirus (HPV) testing into routine cervical cancer screening on precancer and cancer rates by histologic type has not been well described. Calendar trends in diagnoses were examined using data from Kaiser Permanente Northern California, which introduced triennial HPV and cytology co-testing in 2003 for women aged ≥30 years.

methodsWe examined trends in cervical precancer (cervical intraepithelial neoplasia grade 3 [CIN3] and adenocarcinoma in situ [AIS]) and cancer (squamous cell carcinoma [SCC] and adenocarcinoma [ADC]) diagnoses per 1000 screened during 2003-2018. We examined ratios of squamous vs. glandular diagnoses (SCC:ADC and CIN3:AIS).

resultsCIN3 and AIS diagnoses increased approximately 2% and 3% annually, respectively (p

conclusionsSince its introduction at KPNC, co-testing increased the detection of CIN3 over time, which likely caused a subsequent reduction of SCC. However, there has been no observed decrease in ADC. One possible explanation for lack of effectiveness against ADC is the underdiagnosis of AIS. Novel strategies to identify and treat women at high risk of ADC need to be developed and clinically validated.

Indexed as

Early Detection of CancerPapillomavirus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsAdenocarcinomaAdenocarcinoma in SituAdultAgedCaliforniaCarcinoma, Squamous CellCytodiagnosisFemaleHuman Papillomavirus VirusesHumansMiddle AgedPrecancerous ConditionsAdenocarcinoma (ADC)Adenocarcinoma in situ (AIS)Cervical cancerCervical intraepithelial neoplasia grade 3 (CIN3)Cervical precancerCo-testingCytologyHuman papillomavirus (HPV)PapSquamous cell carcinoma (SCC)

Identifiers

PMID38301311
PMCPMC11179988
OpenAlexW4391378126

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.